Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1)

9 Oct 2020

Abstract excerpt

Histone demethylase LSDl (KDMlA) belongs to the flavin adenine dinucleotide (FAD) dependent family of monoamine oxidases and is vital in regulation of mammalian biology. Dysregulation and overexpression of LSD1 are hallmarks of a number of human diseases, particularly cancers that are characterized as morphologically poorly differentiated. As such, inhibitors of LSD1 have potential to be beneficial as a cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Gestational Trophoblastic Disease Studies
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33034194
DOI: 10.1021/acs.jmedchem.0c00978

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1)PMID 33034194Read ↗

Reversible Inhibitors of LSD1 as Therapeutic Agents in Acute Myeloid Leukemia: Clinical Significance and Progress to DateSemantic proximity Read ↗

Advances Toward Lsd1 Inhibitors for Cancer TherapySemantic proximity Read ↗

Inhibitors of LSD1 as a potential therapy for acute myeloid leukemiaSemantic proximity Read ↗

Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenograftsSemantic proximity Read ↗

The Novel LSD1 Inhibitor ZY0511 Suppresses Diffuse Large B Cell Lymphoma Proliferation by Inducing Apoptosis and AutophagySemantic proximity Read ↗

Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemiaSemantic proximity Read ↗

Discovery of WS-384, a first-in-class dual LSD1 and DCN1-UBC12 protein-protein interaction inhibitor for the treatment of non-small cell lung cancer (NSCLC)Semantic proximity Read ↗

A phase 1 trial of the oral DNA methyltransferase inhibitor CC‐486 and the histone deacetylase inhibitor romidepsin in advanced solid tumorsSemantic proximity Read ↗

Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-trans retinoic acid in acute myeloid leukemia across subtypesSemantic proximity Read ↗

Pharmacological inhibition of LSD1 triggers myeloid differentiation by targeting GSE1, a novel oncogene in AMLSemantic proximity Read ↗

LSD1 Performs Demethylase-Independent and Context-Specific Roles in Ewing SarcomaSemantic proximity Read ↗

Pharmacological inhibition of LSD1 triggers myeloid differentiation by targeting GSE1 oncogenic functions in AMLSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.